Latham & Watkins Advises Angion Biomedica in its Initial Public Offering and Concurrent Private Placement

Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, has announced the pricing of its initial public offering of 5 million shares of common stock at a public offering price of US$16 per share, for gross proceeds of US$80 million, before deducting the underwriting discounts and commissions and offering expenses. All of the shares of common stock are being offered by Angion. Angion has also granted the underwriters a 30-day option to purchase from Angion up to an additional 750,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. Angion’s common stock has been approved for listing on The Nasdaq Global Select Market and has begun trading under the ticker symbol “ANGN.”

In addition to the shares being sold in the initial public offering, Angion has agreed to sell an additional 1,562,500 shares of its common stock in a concurrent private placement at at a public offering price of US$16 per share to entities affiliated with Vifor International, Ltd., an existing stockholder.

Latham & Watkins LLP represents Angion in the offering and private placement with a Bay Area-based team led by partners Patrick Pohlen and Miles Jennings, with associates Vishal Ganesan and Taimi Jacobson. Advice was also provided on tax matters by Bay Area partner Grace Lee; on benefits and compensation matters by Bay Area partner Ashley Wagner; and on regulatory matters by Washington, D.C. partner John Manthei, Bay Area counsel Betty Pang and Heather Deixler, and San Diego counsel Amy Speros.